visa digital currency Top snippets

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Ministry of Finance of Thailand: It is estimated that the global minimum corporate tax of 15% will be implemented from January 2025.Organic fluorides in two underground waters in Tochigi Prefecture, Japan exceeded the standard. On the 13th, local time, it was learned that the government department of Tochigi Prefecture in Japan said on the same day that organic fluorides exceeding Japan's provisional safe range were detected in the underground waters of two wells located in Ghost Nuqiu, Zhengang City. (CCTV News)

Beizheng 50 rose more than 1%, Huayang Racing Car had a daily limit of 30CM, and Ricky Zhizao, Fuheng New Materials and Bai Xinglong rose more than 10%.Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.

Li Dongsheng said that low-price competition has no way out, and it will only get involved. On December 11th, at TCL Global Innovation Conference, founder Li Dongsheng said that in the current market competition, low-price competition has no way out, and it will only get involved in endless "involution". To surpass its competitors, it is necessary to strive for more breakthroughs in high-end products. He Jun, vice president of TCL Industry, talked about the current development of industrial software enterprises in China in a subsequent interview. He also said that from the aspects of financing environment and market support for enterprises, China is not an environment where good software enterprises can be born at present, but in the long run, industrial software may make a breakthrough in China software, and this time will not be very fast, and it will not be seen for three or five years.The concept of robot bottomed out and Tianqi shares rose linearly, and Tianqi shares rose linearly. Before that, the construction industry went out of 9 boards in 10 days, Astar went out of 13 boards in 21 days, and Tongda Power went up. Hanyu Group, Maihe, Jiangsu Reilly, Hanwei Technology and Best were among the top gainers.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.